A targeted multi-omics approach reveals *paraoxonase-1* as a determinant of obesity-associated fatty liver disease

Sara Diels¹, Bart Cuypers²,³, Asta Tvarijonaviciute⁴, Bruno Derudas⁵, Evelien Van Dijck¹, An Verrijken⁶,⁷, Luc F. Van Gaal⁶,⁷, Kris Laukens²,³, Philippe Lefebvre⁵, Jose J. Ceron⁴, Sven Francque⁷,⁸, Wim Vanden Berghe⁹ and Wim Van Hul¹*

**Abstract**

**Background:** The multifactorial nature of non-alcoholic fatty liver disease cannot be explained solely by genetic factors. Recent evidence revealed that DNA methylation changes take place at proximal promoters within susceptibility genes. This emphasizes the need for integrating multiple data types to provide a better understanding of the disease's pathogenesis. One such candidate gene is *paraoxonase-1* (*PON1*). Substantial interindividual differences in PON1 are apparent and could influence disease risk later in life. The aim of this study was therefore to determine the different regulatory aspects of PON1 variability and to examine them in relation to the predisposition to obesity-associated fatty liver disease.

**Results:** A targeted multi-omics approach was applied to investigate the interplay between PON1 genetic variants, promoter methylation, expression profile and enzymatic activity in an adult patient cohort with extensive metabolic and hepatic characterisation including liver biopsy. Alterations in PON1 status were shown to correlate with waist-to-hip ratio and relevant features of liver pathology. Particularly, the regulatory polymorphism rs705379:C > T was strongly associated with more severe liver disease. Multivariable data analysis furthermore indicated a significant association of combined genetic and epigenetic PON1 regulation. This identified relationship postulates a role for DNA methylation as a mediator between PON1 genetics and expression, which is believed to further influence liver disease progression via modifications in PON1 catalytic efficiency.

**Conclusions:** Our findings demonstrate that vertical data-integration of genetic and epigenetic regulatory mechanisms generated a more in-depth understanding of the molecular basis underlying the development of obesity-associated fatty liver disease. We gained novel insights into how NAFLD classification and outcome are orchestrated, which could not have been obtained by exclusively considering genetic variation.

**Keywords:** PON1, NAFLD, Obesity, Genetics, Methylation, -Omics, Integrative analysis

---

**Background**

Non-alcoholic fatty liver disease (NAFLD), characterized by significant lipid deposition in hepatocytes, is set to become the most common liver disease worldwide [1]. While clinical, demographic and environmental factors are implicated in the development of NAFLD, obesity has been recognized as one of the main risk factors [2].

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
The disease affects 25% of the world population on average and increases up to 65–90% in patients with obesity [3, 4]. These high prevalence rates indicate NAFLD as an important health concern and emphasize the need for disease management. Moreover, the potential transition of isolated steatosis (i.e. NAFL) to more severe non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis can be recognized as a major contributor to adverse health outcomes (e.g. heart disease, cancer, Covid-19) and mortality in the general population [5–7]. Although accurate prevention and treatment are clearly required, they are challenging as obesity and associated NAFLD are complex heterogeneous diseases for which the mechanisms that contribute to their onset and progression remain only partially elucidated.

The multifactorial nature of both disorders implicate the presence of dietary habits, physical activity, genetics, epigenetics and the environment as important aspects of its pathogenesis. Numerous studies have estimated that 40–70% of the interindividual variability in body mass index (BMI) can be attributed to genetic factors [8–14]. Given this estimated heritability, extensive genome-wide association studies have been performed to determine the influence of common and rare variants in the pathogenesis of complex metabolic disease. Even though a large number of obesity-associated loci were identified (>500), the proportion of variance explained (16–40%) remains lower than the proposed heritable risk [15]. The same is true for NAFLD/NASH, for which several single nucleotide polymorphisms (SNPs) have been identified as genetic modifiers [16]. This indicates the need to explore other forms of genetic variation concerning complex hepatometabolic diseases. An important role must be attributed to the interaction between genetics and the environment. The “common disease genetic and epigenetic” hypothesis proposes that in addition to genetic variation, epigenetics provides an added layer of variation that mediates the gene-environment relationship [17, 18]. It has been demonstrated that there is a significant interplay between obesity-associated genetic variants and environmental factors (e.g. diet, endocrine disruptors, medication) with DNA methylation changes at proximal promoters and enhancers [19]. This highlights the importance of integrating genetic and epigenetic data to provide a more detailed understanding of the disease pathophysiology. Although epigenetic regulation of metabolic health also involves dynamic changes in histone modifications, chromatin accessibility, and RNA interference, most clinical diagnostic studies focus exclusively on associations between genetic versus DNA methylation changes [20]. In general DNA methylation changes are more robust than chromatin changes, which typically are transient and susceptible to a quick turnover [21]. Moreover, since most preserved clinical patient samples (liver biopsy material) contain limited amounts of gDN, clinical diagnostic epigenetic biomarker platforms for DNA methylation quantification are most suitable for sensitive and accurate detection of small quantitative DNA methylation changes at nucleotide resolution, rather than poor quantitative methods measuring regional chromatin changes [22].

Based on preliminary data from our lab and others, we hypothesize that paraoxonase-1 (PON1) is a potential determinant in the development of hepatometabolic disease. PON1 is a multifunctional enzyme synthesized in the liver and secreted in the plasma where it associates with high-density-lipoproteins (HDL). It hydrolyses a wide variety of substrates (e.g. lactones, organophosphorus pesticides, arylesterase) and is best known for its antioxidant and anti-inflammatory properties by detoxification of low-density-lipoproteins (LDL) and HDL metabolites [23–26]. Recent advances from association, (epi)genetic and animal studies further emphasize a protective role of PON1 against environmental exposure, obesity and NAFLD. A previous study by our research group identified remarkable associations between the PON1 genotype and adverse epigenetic marks in endocrine pathways related to childhood obesity and high body fat content at school age [27]. More particularly, we found that (1) T-allele carriers of the regulatory variant rs705379:C>T have higher DNA-methylation values at the PON1 promoter region, negatively affecting organophosphorus pesticide hydrolysis, and (2) the coding variant rs662:T>C influences methylation of genes in several relevant pathways involved in the regulation of appetite and type II diabetes mellitus signalling. Other studies have also associated reduced PON1 expression with adverse lipid metabolism and recognized this as a risk factor for obesity, liver steatosis and its more severe subtype steatohepatitis [28–30]. This link has been confirmed by the observation that pon1-deficient mice, fed a high-fat high-cholesterol diet, develop severe steatosis in the liver [31]. Genetic studies in patients with obesity further indicate a possible correlation of the disease occurrence with PON1 polymorphisms [28, 32]. However, many inconsistencies and unanswered questions remain.

Current PON1 research in obesity and NAFLD focused on either genetic, epigenetic or functional data to explain its function in pathophysiology. None of these studies have combined these different elements to examine complex obesity phenotypes in relation to PON1 polymorphisms, DNA methylation status and associated changes in gene expression and enzymatic activity. The availability of a hepatometabolic patient cohort, with extensive clinical data from different patient samples, enabled us to investigate PON1 variability in a larger context than...
previously considered. Therefore, the aim of our study was to integrate these different data types to evaluate to what extent PON1 status is associated with NAFLD presence and severity and with the associated metabolic dysregulation.

Results
Variability within the different PON1 -omics levels was explored in a hepatometabolic patient cohort (HEPADIP cohort) to identify clinicopathological associations of PON1 regulation with predisposition to obesity-associated fatty liver disease. The complete study population consisted of adult patients (71.5% females, 28.5% males) with a weight-related problem, most of whom were diagnosed with obesity (95.8% of the overall cohort of 790 patients). For 329 participants (41.6%), none of the criteria to propose a liver biopsy were present and therefore no histological characteristics were available. In the other patients \( N_{\text{biopsy}} = 461 \), at least one criterion was met or a liver biopsy was proposed as the patient underwent bariatric surgery. The distributions \((x:y:z)\) according to the grade of steatosis, ballooning, lobular inflammation, adjusted SAF activity, the NAFLD Activity Score (NAS), and the stage of fibrosis were determined and showed an overrepresentation of NAFLD stage 3 patients “NASH + fibrosis grade 1” (45.6% of the liver biopsy cohort of 461 patients). The mean, standard error, minimum and maximum for all clinical and biochemical parameters as well as the absolute values for categorical variables, evaluated in this study, are listed in Table 1. Different subcohorts were present dependent on the PON1 level examined (Additional file 1: Fig. S1). The main characteristics for each of these subpopulations can be found in Additional file 1: Tables S1–S3.

Common polymorphisms and promoter methylation define PON1 status

Genotype-specific regulation of PON1 status
The complete HEPADIP cohort was genotyped to evaluate whether the three common polymorphisms rs705379:C>T (NM_000446.6:c.-108C>T), rs854560:A>T (NP_000437.3:p.Leu55Met) and rs662:T>C (NP_000437.3:p.Gln192Arg) were associated with PON1 expression and PON1 lactonase and arylesterase activity. A strong correlation \((q < 0.001; \text{Additional file 1: Table S4})\) was present between the SNPs and both enzymatic activities. High activity was observed in patients carrying the C-allele of regulatory polymorphism rs705379 and in A-allele carriers and C-allele carriers of coding variants rs854560 and rs662, respectively (Fig. 1). The same genetic effect was found for PON1 expression (Additional file 1: Fig. S2). However, a significant association could only be assigned to rs854560:A>T \((p = 0.0304; \text{EE} = 0.18 \text{ change in methylation compared to A-allele carriers}; \text{STDE} = 0.0757)\), which did not persist after multiple testing correction \((q = 0.0912)\). The genetic effects on PON1 status were independent; i.e. none of the common polymorphisms were in linkage with each other [33]. The three PON1 polymorphisms together explain 30.5% of lactone-hydrolysing activity and 58% of arylester-hydrolysing activity.

Methylation controls PON1 status in a location-dependent manner
The DNA methylation level for a total of 11 CpG sites was measured at the PON1 promoter region. Comparison of methylation variability across the 11 CpG sites revealed a similar pattern between ten of the distinct CpGs for genetics, expression and activity (Additional file 1: Fig. S3–S5). Only CpG site -108, which is also known as the location of SNP rs705379:C>T, showed a deviating pattern. Accordingly, methylation parameters were considered as average promoter methylation (summed average of 10 CpG sites) and -108 methylation. Overall, methylation level percentages varied between 6–60%; lower methylation levels were observed (CpG-108_mean = 10.4%) at CpG site -108 in comparison to the average promoter methylation (CpG_mean = 27.9%).

The effect of epigenetics on PON1 status was assessed and demonstrated a significant association between average promoter hypermethylation and reduced expression \((p = 0.01, \text{EE} = −0.26 \text{ change in expression in relation to increased methylation}; \text{STDE} = 0.09321; q = 0.02; \text{Additional file 1: Fig. S6A})\). The opposite effect was found for -108 methylation (hypomethylation results in decreased expression), although this was not significant \((p = 0.143, \text{EE} = 0.16, \text{STDE} = 0.1045; q = 0.143; \text{Additional file 1: Fig. S6B})\). The same pattern was equally present for both enzymatic activities; increased average promoter methylation led to decreased activity while increased -108 methylation resulted in elevated activity levels (Fig. 2).

All these correlations were significant, except for -108 DNA methylation associated with lactone-hydrolysing activity (Additional file 2: Table S6).

Besides evaluating the association of epigenetics with PON1 expression and activity, we also screened for methylation quantitative trait loci (meQTLs). Statistics revealed that the screened polymorphisms can be recognized as cis-meQTLs; and significant methylation differences were found for all SNPs except for rs854560:A>T on average promoter methylation (Fig. 3; Additional file 1: Table S5 and Additional file 2: S6).

Determinants of PON1 variability outlined
The combined effects of genetics and epigenetics as well as the interrelation between expression and activity were
examined in the different HEPADIP subcohorts (Additional file 1: Fig. S1; statistical analysis models glm(activities ~ SNPs*methylation*expression), glm(activities ~ expression), glm(expression ~ SNPs*methylation), were simplified and significance determined).

Multivariable regression analysis showed a combined independent effect of genetics and average promoter methylation on both activities. Polymorphic variant rs854560:T (NP_000437.3:p.55Met) was associated with high average promoter methylation and consequently low activity levels. The combination of SNP rs854560 and average promoter methylation together explained 49.7% and 48.6% of variability for lactone- and arylester-hydrolysing activity, respectively. For SNP rs662:T > C, the highest methylation M-values and lowest activity was observed in T-allele carriers (NP_000437.3:p.Gln192), together describing 75% of arylesterase status. The determinants for lactonase status were more complex, with sex also having a significant independent impact on enzymatic activity (37.5% variability). The sex-specific effect translates into low lactonase levels and high average methylation in T-allele male carriers. Furthermore, no combined (epi)genetic effect was for the different polymorphisms with -108 methylation and for rs705379:C > T with average promoter methylation. These findings generally

| Table 1  | Study population characteristics |
|-----------------|---------------------------------|
| Age (years)     | 43 ± 0.45 (18–74)               |
| Weight (kg)     | 110.7 ± 0.8 (65.8–226.6)       |
| Height (m)      | 1.68 ± 0.003 (1.47–2.06)       |
| BMI (kg/m²)     | 38.8 ± 0.22 (24.97–69.13)      |
| Waist circumference (cm) | 116.7 ± 0.5 (83.5–193) |
| Hip circumference (cm) | 122.2 ± 0.4 (95–160) |
| Waist-to-hip ratio | 0.96 ± 0.004 (0.66–1.35)     |
| Fat free mass (kg) | 56.2 ± 0.4 (36.5–110)         |
| Fat mass (kg)   | 54.3 ± 0.5 (16.9–134.5)        |
| Fat mass (%)    | 48.87 ± 0.27 (22.3–65.3)       |
| Total abdominal adipose tissue (cm²) | 799.5 ± 6.6 (246–1386) |
| Visceral abdominal tissue (cm²) | 195.9 ± 3.2 (29–567)          |
| Subcutaneous abdominal tissue (cm²) | 603.6 ± 5.6 (166–1059)    |
| Systolic blood pressure (mmHg)  | 127.1 ± 0.5 (90–180)       |
| Diastolic blood pressure (mmHg) | 75.45 ± 0.37 (49–115)       |
| Creatinine kinase (mg/dL)       | 0.81 ± 0.006 (0.38–1.64)    |
| Aspartate aminotransferase (U/L) | 23.6 ± 0.5 (7–133)        |
| Alanine aminotransferase (U/L)  | 35.8 ± 0.8 (7–265)           |
| Alkaline phosphatase (U/L)      | 79.94 ± 0.79 (30–236.03)     |
| gamma-glutamyltransferase (U/L) | 43.43 ± 1.19 (11.79–315.16) |
| Total cholesterol (mg/dL)       | 199 ± 1.40 (75–400.44)       |
| High-density-lipoprotein Cholesterol (mg/dL) | 50.83 ± 0.49 (24–107.17) |
| Triglycerides (mg/dL)           | 152.97 ± 2.93 (17–823.01)    |
| Low-density-lipoprotein cholesterol (mg/dL) | 117.81 ± 1.24 (17.6–294.76) |
| Insulin resistance (HOMA)       | 4.27 ± 0.23 (0.07–147.65)    |
| Steatosis (0:1:2:3)             | 109.15:119.2          |
| Ballooning (0:1:2:3)            | 139:187:135           |
| Lobular inflammation (0:1:2:3)  | 148:208:75:30        |
| Fibrosis stage (0:1:2:3:4)      | 287:91:51:28:3        |
| Adjusted SAF activity (0:1:2:3:4:5) | 100:71:112:44:16:14 |
| NAFLD activity score (0:1:2:3:4:5:6:7:8) | 75:44:48:62:84:60:50:30:8 |
| NAFLD staging (1:2:3:4)         | 61:80:210:53         |

Patient clinical and biochemical variable statistics are represented for the complete HEPADIP cohort (Ntotal = 790; 565 females—225 males). Values are expressed as the mean ± standard error of the mean. Lower and upper limits are indicated as minimum/maximum. The distribution of patients (x:y:z) according to the histological characteristics (Nliver biopsy = 461) are shown as absolute values. The histological criteria were evaluated by the NASH-CRN scoring system.
confirmed previous pairwise association testing results (Figs. 1, 2 and 3).

In addition, the influence of confounding factors (sex, age, medication, alcohol and smoking habits were added to previous statistical analysis models glm(activity ~ SNPs*methylation*expression), glm(activity ~ expression), glm(expression ~ SNPs*methylation) and simplified to determine significance) was tested and designated a medication-dependent effect of \( \beta = -1.26 \) change in enzymatic activity in relation to increased methylation on lactonase activity (\( p = 0.008 \), EE = -1.26 change in enzymatic activity in relation to increased methylation in case medication was taken; STDE = 0.436; \( N = 28 \)). Patients not on medication at the start of the HEPADIP project showed higher activity levels in case of higher methylation (previously mentioned and shown in Figs. 2 and 4). However, this effect (explaining 28.9% of the enzymatic variability) was no longer apparent if a patient took any of the medicine types examined in our population (see Sect. 5.7 for all medical treatment variables considered).

The correlation between PON1 activity and transcript expression was tested. Although we observed a positive trend between PON1 expression level and lactonase activity (\( p = 0.09 \); EE = 1.23 change in lactonase activity in relation to increased expression; STDE = 0.7059), no direct relationship between relative expression and arylesterase activity was determined (\( p = 0.124 \); EE = 1.32; STDE = 0.8173). Moreover, no significant correlation was identified for the combined effect of PON1 genetics and epigenetics on expression (Additional file 2: Table S6). The same applied for both enzymatic activities

confirmed previous pairwise association testing results (Figs. 1, 2 and 3).

In addition, the influence of confounding factors (sex, age, medication, alcohol and smoking habits were added to previous statistical analysis models glm(activity ~ SNPs*methylation*expression), glm(activity ~ expression), glm(expression ~ SNPs*methylation) and simplified to determine significance) was tested and designated a medication-dependent effect of \( \beta = -1.26 \) change in enzymatic activity in relation to increased methylation on lactonase activity (\( p = 0.008 \), EE = -1.26 change in enzymatic activity in relation to increased methylation in case medication was taken; STDE = 0.436; \( N = 28 \)). Patients not on medication at the start of the HEPADIP project showed higher activity levels in case of higher methylation (previously mentioned and shown in Figs. 2 and 4). However, this effect (explaining 28.9% of the enzymatic variability) was no longer apparent if a patient took any of the medicine types examined in our population (see Sect. 5.7 for all medical treatment variables considered).

The correlation between PON1 activity and transcript expression was tested. Although we observed a positive trend between PON1 expression level and lactonase activity (\( p = 0.09 \); EE = 1.23 change in lactonase activity in relation to increased expression; STDE = 0.7059), no direct relationship between relative expression and arylesterase activity was determined (\( p = 0.124 \); EE = 1.32; STDE = 0.8173). Moreover, no significant correlation was identified for the combined effect of PON1 genetics and epigenetics on expression (Additional file 2: Table S6). The same applied for both enzymatic activities
concerning expression and PON1 genetic factors. Significance was not reached, possibly as a result of low sample size (N ≤ 22; Additional file 1: Fig. S1).

**PON1 status and obesity-associated liver abnormalities**

**Regulatory polymorphism rs705379:C as a risk variant for NAFLD severity**

Pairwise association testing was performed to explore PON1 status in relation to the hepatometabolic phenotype (all variables listed in Table 1 were selected as response variable while the different PON1 levels, including SNPs, methylation, expression and activity, were selected as explanatory variable). A direct correlation between promoter SNP rs705379:C>T and different histological findings was shown by statistical analyses (Fig. 5). Patients carrying the C-allele showed more prominent hepatocellular ballooning (p < 0.001; q = 0.005), higher lobular inflammation (p = 0.02; q = 0.06), and more severe activity (p = 0.003; q = 0.026). Accordingly, homozygous C-allele carriers were diagnosed with a more progressive NAFLD phenotype (p = 0.01; q = 0.04). Their odds of being diagnosed with isolated steatosis (i.e. NAFL) over no NAFLD was 5.4 times higher (p = 0.01, 95%CI 4.13–6.74) and even increased to an odds ratio of 15.9 and 10 for NAFLD categories “NASH + fibrosis grade 1” (p < 0.001, 95%CI 14.76–17.14) and “NASH + fibrosis grade 2–4” (p < 0.001, 95%CI 8.70–11.23), respectively. This was counteracted in case the patient was taking medication (see Sect. 5.7 for all medical treatment variables considered). Subsequently, a 0.27 fold decrease of being diagnosed with NAFLD category “NASH + fibrosis grade 2–4” (p = 0.01, 95%CI 0.04–2.23) was observed in homozygous C-allele carriers.
Vertical data integration of PON1: omics levels exposes a link with obesity-related liver disease

Integrative analysis of the different PON1 -omics data layers (Additional file 1: Fig. S1; all variables listed in Table 1 were selected as response variable while the different PON1 levels, in combination with confounding factors such as age and sex, were selected as explanatory variable) demonstrated a significant positive relationship between PON1 activity (both for arylesterase and lactonase) and lipid parameters HDL and total cholesterol ($q < 0.01$, $q < 0.01$, $EE_{chol-aryl} = 5.13$, $EE_{HDL-aryl} = 6.16$, $EE_{HDL-lac} = 2.41$, $EE_{HDL-lac} = 3.57$ increase in relation to higher PON1 levels; Additional file 1: Fig. S7). The association with HDL was further independently influenced by sex; males tended to have lower HDL levels compared to females ($p < 0.001$). Together, enzymatic activity and sex explained 16.8–19.1% of HDL variability. Furthermore, determination of the methylation level at the PON1 promoter region showed a significant positive relationship at CpG site -108 with gamma-glutamyltransferase (GGT; $p = 0.003$, $EE = 0.3507$ change in GGT in relation to increased -108 methylation; STDE = 0.1088; $q = 0.049$).

Multivariable statistics combining PON1 polymorphisms with methylation data illustrated an association with Waist-to-Hip Ratio (WHR). An interaction between rs705379:C>T and average promoter methylation was exposed by multivariable statistics and
indicates that patients homozygous for the C-allele show high WHR when average promoter methylation is low. In contrast, heterozygous patients and patients homozygous for the T-allele have high WHR if hypermethylation was present (Fig. 6; \( p = 0.006 \)). A sex-specific effect (33%; \( p < 0.001 \); EE = 0.13 WHR increase in female patients; STDE = 0.027505) was also found, which together with the combined (epi)genetic relationship (13.9%; EE = 0.006 WHR increase in T-allele female carriers with increased average promoter methylation; STDE = 0.002), described 46.9% of the variability in WHR.

No direct or combined associations were found between PON1 variability and BMI.

**Discussion**

A targeted multi-omics approach was applied to examine the role of PON1 in relation to obesity-associated fatty liver disease. Different levels of variability including *PON1* genetic polymorphisms, DNA methylation and confounding factors such as sex, medication, etc. were considered to understand the mechanisms that regulate its expression level and enzymatic activity. Identification of signatures that define PON1 status could be valuable to clarify their influence on the pathophysiology of hepatometabolic disease.

Pairwise association testing revealed a correlation between the regulatory polymorphism rs705379:C>T (NM_000446.6:c.-108C>T) and different histological
liver features (Fig. 5). More specifically, our results indicate that patients carrying the C-allele are at a higher risk of being diagnosed with NAFLD and the more severe subtype NASH. A molecular basis for this relationship can be found in the location of this variant on the \( PON1 \) locus. Risk variant rs705379:C is positioned in a site within the promoter region of \( PON1 \) known to bind transcription factor Specific protein 1 (Sp1) in an interactive manner with sterol regulatory element-binding protein-2 (SREBP-2). This latter protein plays a central role in lipid metabolism by the regulation of cellular cholesterol biosynthesis, uptake and excretion [34, 35]. Overexpression of SREBP-2 has also been associated with free cholesterol accumulation in the liver and consequently NAFLD pathogenesis [36]. Particularly, liver disease severity seems to be strongly related to dysregulation of SREBP-2 as animal and clinical studies have demonstrated that alterations in transcriptional regulators of cholesterol homeostasis mediate the progression of steatosis to steatohepatitis [37–39].

Thorough examination of the different PON1 -omics layers enables us to postulate about the involvement of complex (epi)genetic mechanisms and gene expression modulation as an explanation for the observed \( PON1 \) association with NAFLD severity. Polymorphism rs705379:C>T can be observed as a CpG-SNP, which is known to introduce or remove a CpG site at position -108. The outcome is a drastic change in the promoter regulatory status through adaptation of the substrate. This is reflected by hypermethylation-induced expression and activity perceived in C-allele carriers versus T-allele carriers (Figs. 1 and 3). Additionally, analysis has shown that CpG-SNPs not only interfere with the DNA methylation status of their own CpG site but that they can also alter methylation patterns of CpG sites in close proximity [15]. Such a relationship was found for rs705379:C>T.
with average PON1 promoter methylation in our patient cohort (Fig. 3). The significant association of average promoter hypermethylation both with reduced PON1 expression (Additional file 1: Fig. S6) and both enzymatic activities (Fig. 1) suggests that alterations in gene expression and catalytic efficiency could be the intermediate step between (epi)genetics and the disease phenotype. Research designated that methylation-disrupting SNPs can change expression and/or activity by different mechanisms (e.g. alternative splicing, transcription factor binding, protein folding). A plausible explanation for our results is the regulation of gene expression through the perturbation of transcription factor binding site (TFBS) affinity. TFBS analysis indicated that position -108 occurs in the recognition sequence of transcription factor Sp1 [40, 41]. Confirmation of this finding was provided by a study by Deakin et al. [42], which demonstrated a complex formation between Sp1 and the -108 polymorphic site. Moreover, it was demonstrated that overexpression of Sp1 enhances PON1 transcription and that this is mediated by methylation [30, 43–45]. Sp1 has thus been shown to bind unmethylated regulatory regions thereby preventing DNA methyltransferases from accessing the promoter and activating transcription [46]. Perturbation of TFBS affinity is found when a cytosine is replaced by a thymine at position -108. In this case, the recognition sequence for Sp1 is disrupted, hypermethylation is present and transcriptional repression is observed. In accordance with Huen et al. [30], we believe that this gene-specific transcriptional silencing might explain the genotype differences of rs705379:C > T (NM_000446.6;c.-108C > T) with average promoter methylation and PON1 status. Accordingly, the C > T nucleotide substitution will disrupt the interaction between proteins Sp1, SREBP-2 and the PON1 promoter (Fig. 7). This was reflected in our cohort by a decrease in enzymatic activity (arylesterase and lactonase) and disease risk, and suggests that upregulation of SREBP-2 and high PON1 activity both promote NAFLD pathogenesis.

Our hypothesis is supported by the association observed between -108 hypermethylation and increased plasma GGT levels. GGT is one of the hepatic enzymes traditionally used in first-line indicative tests to predict NAFLD development [47]. Alterations in GGT levels have been associated with markers of chronic inflammation (e.g. fibrinogen) and oxidative stress (e.g. lipid peroxides), both hallmarks of NAFLD progression [48, 49]. Our previously identified relationship between -108
hypermethylation and increased arylesterase activity (Fig. 2) thus indicates that the presence of high PON1 levels in the blood is associated with increased GGT and high-risk disease prevalence. Likewise, the observed medication-dependent effect on NAFLD staging (0.27 fold decrease in being diagnosed with severe NASH) was associated with -108 methylation and consequently lactonase activity (Fig. 4). Patients not taking any medication showed increased activity levels in case of -108 hypermethylation. Medication-taking behaviour abolished this relationship and indicates the importance of epigenetics as an intermediate between environmental factors and PON1 status. Various pharmaceuticals have been reported to modify methylation patterns in gene promoter regions, thus affecting gene expression and protein levels. Our results thus suggest that the previously mentioned hypermethylation-induced transcriptional activation will be altered as a result of drug exposure, and thereby reducing the odds of a more progressive NAFLD diagnosis. The finding that a higher WHR is measured in C-allele carriers of SNP rs705379 with decreasing methylation levels reinforces the (indirect) link between high PON1 activity and NAFLD pathogenesis (Fig. 6). Our formerly observed inverse correlation between average PON1 promoter methylation and both enzymatic activities (Fig. 2) shows that this increase in WHR is likewise associated with elevated PON1 levels. The knowledge that WHR is an important factor in NAFLD development further supports the importance of epigenetic regulation in the disease process.

**Fig. 7** Molecular mechanism proposed for PON1 in NAFLD pathophysiology. Schematic representation of the suggested gene-regulatory effect of rs705379:C>T on NAFLD pathogenesis. The PON1 polymorphism is located in the promoter region of PON1 and identified to bind transcription factor Specific protein 1 (Sp1) in an interactive manner with sterol regulatory element-binding protein-2 (SREBP-2). Sp1 is known to initiate PON1 transcription in a methylation-dependent manner while SREBP-2 is implicated in cholesterol homeostasis. Two different scenarios are possible depending on which polymorphic variant is present: a SNP rs705379:C results in hypomethylation-induced expression and activity of PON1. Simultaneously, SREBP-2 upregulation is observed resulting in hepatic cholesterol accumulation and increased susceptibility for NAFLD/NASH development. b SNP rs705379:T alters transcription factor binding affinity thereby resulting in hypermethylation-induced silencing, normal SREBP-2 levels and correct functioning of the liver. Figure was created with BioRender.com
sex-specific metric in the evaluation of weight-related disease [50], proposes the rs705379:C (NM_000446.6:c.-108C) variant and consequently high PON1 activity as a determinant for hepatic manifestations in patients affected by obesity rather than a risk factor for the onset of metabolic disease. This is confirmed by the non-significant correlation between BMI and the different PON1 -omics data layers in our study population (Additional file 2: Table S6) and is consistent with the current insights into NASH pathophysiology, which indicate the importance of elevated visceral-to-subcutaneous adipose tissue ratios (cfr. WHR) over a general increase in body weight (cfr. BMI) as an important mechanism of NAFLD initiation and NASH progression [51].

The strength of our experimental design is the extensive examination of multiple PON1 -omics data layers in a large hepatometabolic cohort. It facilitated us to perform a targeted multi-omics approach that enabled us to investigate the relationship between PON1 status and obesity-associated liver pathology as well as to explore the potential involvement of PON1 (epi)genetics in the regulation of its gene expression and catalytic efficiency. PON1 is known to be secreted in the blood circulation where it associates with HDL. This was supported by the observed positive association of PON1 status with cholesterol and HDL. The general assumption is that the presence of both HDL and apolipoprotein A1 (apoA1) are necessary to bind PON1 with high affinity. The binding of HDL particles carrying apoA1 occurs with the N-terminal domain of PON1, thereby stabilizing the enzyme and stimulating its activity [52, 53]. Physiological distribution and PON1 status are thus dependent on the direct binding to phospholipids in association with apoA1. Moreover, we were able to determine the importance of PON1 genetic and epigenetic variation in relation to its status. A genotype-dependent difference was observed for promoter methylation (i.e. meQTL), which further translates into changes in both enzymatic activities (Figs. 1 and 3). This finding suggests that methylation acts as a mediator between PON1 genetics and PON1 activity. Integration of genetic and epigenetic data confirms this assumption and reveals a combined independent effect for rs854560:A>T and rs662:T>C with average promoter methylation on PON1 status (Fig. 2). High average promoter methylation and low activity levels were detected for T-allele carriers of coding polymorphisms rs854560 (NP_000437.3:p.55Met) and rs662 (NP_000437.3:p.Gln192), independent of the hydrolysed substrate. The relationship that was identified can be ascribed to conformational changes in the three-dimensional structure of the enzyme. The rs854560:A>T (NP_000437.3:p.Leu55Met) polymorphism has been associated with alterations in protein stability and consequently PON1 concentration, while rs662:T>C (NP_000437.3:p.Gln192Arg) has been shown to be part of PON1’s catalytic site thereby regulating its enzymatic activity in a substrate-dependent manner [54–56].

A limitation in our study was the restricted availability of RNA samples for gene expression analysis. As we only had 22 biological replicates available, the sample size was too small for a representative PON1 expression distribution over the different genotypes. Consequently, we could not validate the assumption of gene expression modulation as the intermediate mechanism between regulatory variant rs705379:C>T, alterations in TFBS affinity and NAFLD severity. The same limitation applies for pairwise testing of PON1 expression with enzymatic activity (q>0.05). Despite the fact that we found increased promoter methylation to be negatively associated with expression (q=0.02; Additional file 1: Fig. S6A) and that similar relationships between (1) PON1 genetics and expression (Additional file 1: Fig. S2) versus PON1 genetics and activity (Fig. 1) and (2) epigenetics and expression (Additional file 1: Fig. S6) versus epigenetics and activity (Fig. 2) were observed, future experiments in a larger sample set will be necessary to demonstrate its significance and to validate the intuitive hypothesis that gene expression is a major determinant of PON1 status.

Although our study consists of an extensively monitored large obesity cohort with(out) the presence of hepatic manifestations, we only had restricted information on other variables known to influence PON1 status. PON1 is recognized as a multifunctional protein that is modulated by many different exogenous factors (e.g. chemicals, lifestyle, diet). Likewise, its activity can vary depending on different physiological conditions or pathological states [57]. It is therefore difficult to perform studies on PON1 that include all potential confounding factors and caution should be taken for result interpretation, as our study did not include information on the patients’ cardiovascular and neurological states (two disease states known to be correlated with PON1 status) [13, 14].

Another drawback is the cross-sectional nature of our study, as it does not allow us to determine whether the relationship we found between high PON1 activity and hepatic manifestations was a cause or a consequence of obesity and/or NAFLD. Two possible explanations exist that can describe our results being (1) high PON1 activity is a driving force in the development of obesity-associated NAFLD or (2) high PON1 activity is a consequence of obesity and its comorbidity NAFLD. This latter explanation is most consistent with our results and best reflects the general idea that an increase in PON1 exhibits a protective role against the susceptibility for obesity and associated fatty liver disease [28–31].
The observed increase in PON1 activity levels would in this manner reflect a defence mechanism to prevent further hepatometabolic manifestations that lead to the advancement of obesity to NAFLD/NASH. In this manner, our results can be considered as a pilot study indicating the importance of integrating multiple levels of data variation to unravel complex disease mechanisms.

Conclusions
Vertical data-integration of PON1 genetic polymorphisms, epigenetic DNA methylation variation, gene expression profile and enzyme activity revealed a possible molecular mechanism through which the three most frequently studied polymorphisms may influence PON1 status (high activity levels for rs705379:C, rs854560:A and rs662:C). Changes in the epigenetic profile in relation to the genotype propose that methylation acts as a mediator between PON1 genetics and enzymatic activity. The most pronounced effect observed in the present study is a reduction in PON1 levels resulting from average promoter DNA hypermethylation. However, local hypermethylation-induced PON1 activity was also found. Polymorphisms in the coding region of PON1 are attributed to conformational changes with a direct influence on its catalytic efficiency. The relationship between the regulatory CpG-SNP rs705379:C>T and PON1 status is more challenging with a potential involvement of gene expression modulation via Sp1 (Fig. 7). Our findings suggest that increased binding of Sp1 enhances PON1 transcription mediated by hypomethylation. Introduction or removal of a CpG site at position -108 consequently leads to overall transcriptional repression and lower PON1 levels. Furthermore, it is known that Sp1 can bind the promoter region of PON1 in an interactive manner with SREBP-2. Overexpression of SREBP-2 has been associated with hepatic cholesterol accumulation and NAFLD severity. This was reflected in our cohort by the significant correlation between rs705379 C-allele carriers and the higher odds of being diagnosed with a more progressive NAFLD phenotype. We therefore believe that PON1 activity is an important contributor to the pathophysiology of NAFLD/NASH. This assumption was further reinforced by the found association that was found of PON1 status with increased GGT levels and WHR.

Our study results illustrate the relevance of performing integrative multi-omics approaches to gain insights into the crosstalk of different levels of variation in gene function and disease phenotypes. Future longitudinal studies on large obesity cohorts will be necessary to shed light on the causality of the association observed between PON1 status and hepatometabolic disease.

Methods
Patients visiting the obesity clinic of the Antwerp University Hospital (a tertiary referral facility) for a problem of overweight (BMI ≥ 25–29.9 kg/m2) or obesity (BMI ≥ 30 kg/m2), presenting at their own initiative or referred by their treating physician, were consecutively recruited. Every patient underwent a standard metabolic work-up combined with a liver-specific program [58, 59], both approved by the Ethics Committee of the Antwerp University Hospital (reference 6/25/125, Belgian registration number B30020071389) and requiring written informed consent of the patient.

Metabolic work-up
Anthropometric measurements were carried out in the morning, with patients in fasting conditions and undressed. Height was measured to the nearest 0.5 cm and body weight was measured with a digital scale to the nearest 0.2 kg. BMI was calculated as weight (in kg) divided by height (in m) squared. Waist circumference was measured at the mid-level between the lower rib margin and the iliac crest. Hip circumference was measured at the level of the trochanter major. The WHR was calculated by dividing waist circumference by hip circumference. Body composition was determined by bio-impedance analysis as described by Lukaski et al. [60] and body fat percentage was calculated by the formula of Deurenberg et al. [61]. The cross-sectional areas of total abdominal adipose tissue, visceral abdominal tissue and subcutaneous abdominal adipose tissue were measured by a CT-scan at L4-L5 level [62]. Systolic and diastolic blood pressure were determined on the right arm of the patient, after at least 5 min rest, using a mercury sphygmomanometer. Fasting blood samples were taken from an antecubital vein and collected into BD Vacutainer EDTA tubes (Becton Dickinson Medical Devices Co Ltd, Benelux). Serum samples were acquired by blood collection into BD Vacutainer serum separator tubes (Becton Dickinson Medical Devices Co Ltd, Benelux). Lipid profiles including total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were measured. Levels of liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT)] and creatinine kinase were measured. The insulin resistance estimation was assessed using the homeostasis model and was calculated as [insulin (mU/L) × glucose (mmol/L)]/22.5 [63].
Hepatological work-up
Additional blood analyses were performed to exclude classical aetiologies of liver disease (e.g. viral hepatitis and autoimmune disease). The metabolic liver reserve was determined by an aminopyrine breath test and a Doppler ultrasound of the abdomen. The ultrasound appearance of the liver parenchyma was scored by making the sum of the echogenicity of the liver parenchyma compared to the renal parenchyma (0: no hyperechogenicity; 1: mild-to-moderate hyperechogenicity; 2: moderate-to-severe hyperechogenicity) and posterior beam attenuation (0: absent; 1: present) resulting in an ultrasound steatosis score (USS) ranging 0–3. Patients were excluded from the study in case of (1) diagnosis of another liver disease than NAFLD, (2) significant alcohol consumption (>20 g/day) and/or (3) history of bariatric surgery. Longstanding diabetes is a known risk factor for fibrosis and some therapies and interventions for diabetes are known to have an impact on NAFLD pathology. Accordingly, patients previously diagnosed with diabetes were not included as diabetes and its associated treatments were considered major confounding factors for NAFLD pathogenesis. If conversely diabetes was de novo diagnosed, patients were not excluded as de novo diagnosis is not considered as a confounder for the expected results of the liver biopsy. Glucose tolerance status was defined based on the criteria of the American Diabetes Association [64].

Liver biopsy
Patients with suspicion of NAFLD, defined by abnormal liver tests (AST and/or ALT and/or GGT and/or ALP) and/or liver ultrasound abnormality (steatotic liver defined by USS ≥1), were offered a liver biopsy for accurate diagnosis (gold standard). Subsequently, they entered a weight-management program. Some patients underwent bariatric surgery, for whom a liver biopsy was proposed regardless of the criteria. Upon informed consent, a liver biopsy was performed percutaneously (16G Menghini), transjugularly (16G transjugular liver biopsy needle) or perioperative (16G Trucut needle). Haematoxylin–eosin stain, Sirius red stain, reticulin stain and Perl's iron stain were routinely performed on all biopsies.

Different histological features were blindly assessed by two experienced pathologists. NAFLD subtype and severity were defined by use of the NASH Clinical Research Network (NASH-CRN) scoring system [65–67]. They proposed the NAFLD Activity Score (NAS), which evaluates NAFLD lesions by summing component scores for steatosis, lobular inflammation, and hepatocellular balloononing (score ranges from 0 to 8). Despite the fact that this scoring system is widely used by both clinical and research communities, the FLIP-algorithm was suggested in 2012 to evaluate liver biopsies of patients with morbid obesity [68]. In this scoring system, steatosis (S) is scored separately from the activity (A, sum of lobular inflammation and hepatocellular balloononing), resulting in the SAF score (F = fibrosis). As differences are present between both scores in the definition for the grading of hepatocellular balloononing and lobular inflammation, we introduced the adjusted SAF activity (aSAF-A) in our dataset. This variable is an equivalent of the activity parameter used in the FLIP-algorithm and calculated as the sum of lobular inflammation and hepatocellular balloononing scored by the NASH-CRN system. Lastly, we introduced the NAFLD staging parameter used to subclassify the patient population into (1) "no NAFLD", (2) "NAFL", (3) "NASH + fibrosis grade 1" and (4) "NASH + fibrosis grade 2–4".

The complete study protocol was performed according to the Declaration of Helsinki and approved by the Ethics Committee of the Antwerp University Hospital. All authors had access to the study data and had reviewed and approved the final manuscript. An overview of patient samples is presented in Additional file 1: Fig. S1. Anthropometric and biochemical values analysed in the population are summarized in Table 1.

SNP genotyping
Polymorphisms located on the paraoxonase-1 (PON1) locus are indicated as genetic determinants of PON1 variability [30]. Although more than 400 SNPs have been described on chromosomal region 7q21.3, most of the variability can be explained by polymorphisms in the 5’ regulatory region (NM_000446.6:c.-108C>T) and the coding region (NP_000437.3:p.Leu55Met and NP_000437.3:p.Gln192Arg) [69, 70]. The three common polymorphisms rs705379:C>T (NM_000446.6:c.-108C>T), rs854560:A>T (NP_000437.3:p.Leu55Met) and rs662:T>C (NP_000437.3:p.Gln192Arg) were genotyped in the complete HEPADIP patient cohort (N=790; Additional file 1: Fig. S1). Predesigned TaqMan SNP Genotyping Human Assays were used to study the selected SNPs (Applied Biosystems Inc., CA, USA). Genomic DNA was extracted from whole blood samples. Allelic discrimination was performed according to the manufacturer’s protocol with the use of the Lightcycler 480 Real-Time PCR System (Roche, Penzberg, Germany). Quality control was performed by Sanger sequencing three independent samples for each genotype of the analysed PON1 polymorphisms.

Pyrosequencing
Integrative analysis of genetic and epigenetic data holds promise to better understand the pathogenesis of complex diseases such as obesity and NAFLD [15, 71]. Genotype-specific alterations in DNA methylation may be
related to adverse metabolic risk via negative PON1 modulation [27, 72]. For this reason, we assessed DNA methylation status at the PON1 promoter region in a subcohort of the patient population (N=45; Additional file 1: Fig. S1). To select a cis-MeQTL PON1 region of interest for DNA methylation quantification by pyrosequencing, we prioritized the CpG island promoter region, localized in a transcriptional permissive “weak promoter enhancer” chromatin state [73], previously associated with control of gene expression [74].

Briefly, genomic DNA was extracted from the liver using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) and subjected to bisulphite conversion using the EpiTect® Fast Bisulfite Conversion kit (Qiagen, Hilden, Germany). A pyrosequencing approach was applied to measure DNA methylation levels. In summary, amplification of the bisulphite treated DNA fragments was performed using the PyroMark PCR kit (Qiagen, Hilden, Germany). Single stranded PCR products were annealed with the sequencing primer and pyrosequenced on a PyroMark Q24 instrument (Qiagen, Hilden, Germany). DNA methylation of each CpG site was quantitatively assessed using the PyroMark Q24 Advanced software (Qiagen, Hilden, Germany). The Pyro Q-CpG software delivers a quality control report for each sequencing run and only assays which “pass” software quality control requirements were considered. Blank dispensations did not exhibit any intensity signal being significantly above background signals. Software Assay “pass” quality settings confirmed that gDNA was completely bisulphite converted by bisulphite conversion controls at a specific locus (C > T in non CpG context) and unconverted C signal was close to background intensity and did not cross minimal signal threshold. The signal intensity of the expected peaks was at least 30–50 RLU, to be distinguished from background signals [75]. Methylation levels were defined by methylation values (M-values) calculated as the log2 ratio of the intensity signal obtained from the methylated allele versus the unmethylated allele [76]. Assays and biotinylated-reverse, forward and sequencing primers were designed with PyroMark Assay Design 2.0 software (Qiagen, Hilden, Germany).

Gene expression

PON1 gene expression was examined in 22 patients of the HEPADIP cohort for which high quality RNA was available (Additional file 1: Fig. S1). RNA was isolated from human liver biopsy by acid guanidinium thiocyanate-phenol–chloroform extraction [77]. Single-stranded cDNA was synthesized using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems Inc., Foster City, CA, USA). Quantitative real-time PCR was performed with Brilliant II SYBR Green QPCR Master Mix on a Stratagene Mx3005P system (Agilent Technologies, SC, USA). Relative changes in PON1 expression (NM_000446) were normalized to the RNA levels of three housekeeping genes according to the 2^−ΔΔCt method[78]. cDNA primers were designed with the primer-BLAST tool of NCBI. Qualitative gene expression data was guaranteed by the inclusion of negative and no template controls, biological and technical triplicates and reference genes as internal control for normalization.

Activity measurements

PON1 is an ambiguous enzyme capable of hydrolysing a wide variety of substrates including thiolactones, arylestes, organophosphorus pesticides, nerve gases, estrogen esters and lipoproteins [25]. Accordingly, identifying its physiological relevance and native substrate have long been the focus of many studies. Structure–reactivity experiments suggest a native enzymatic activity of PON1 towards lactones with fatty acid oxidation as its major biological function [23, 79, 80]. Paraoxonase and arylesterase are in contrast promiscuous activities able to hydrolyse numerous man-made chemicals [81]. For our study, we determined substrate-specific lactonase and arylesterase activities since the combination most accurately reflects the concentration and activity of PON1 [49, 54]. Paraoxonase activity was not considered as extreme differences (>40 fold) are apparent for paraoxon hydrolysis in relation to genetic polymorphisms [25].

Serum lactonase activity was evaluated by measuring the hydrolysis of 5-thiobutyl butyrolactone (TBBL). This method involves the use of a chromogenic lactone structurally resembling the proposed natural lipolactone substrate. Serum samples were prepared in sample buffer containing 50 mmol/L Tris and 1 mmol/L CaCl2 (pH = 8.0) in a 20-fold dilution. Each well of a 96-well plate was loaded with 1 μL 100 mmol/L 5,5′-dithio-bis-2-nitrobenzoic acid in dimethyl sulfoxide, 45 μL of 4% acetonitrile solution in sample buffer, 5 μL of diluted serum, and 50 μL of sample buffer. The kinetic reaction was initiated by adding 100 μL of substrate buffer, consisting of 0.4 mmol/L TBBL solution in sample buffer, to each well of the 96-well plate. The reaction was monitored at 412 nm in an automated microplate reader at 37 °C (PowerWave XS, Bio-Tek Instruments Inc., Winooski, VT, USA). Spontaneous TBBL hydrolysis, defined as the hydrolysis rate in the absence of serum, was subtracted from all measurements. Lactonase activity was expressed as units per millilitre of serum, in which 1 unit equals 1 mmol of TBBL hydrolysed/min. The molar extinction coefficient used to calculate the rate of
The non-enzymatic hydrolysis of p-nitrophenol acetate to p-nitrophenol. The working reagent consisted of 50 mmol/L Tris–HCl (pH = 8.0) with 1 mmol/L CaCl₂. The substrate was prepared in water as a separate starting reagent (2.5 mmol/L p-nitrophenyl acetate). The formation rate of p-nitrophenol was evaluated by adding 2 µL undiluted sample to 300 µL of the working reagent, after which 72 µL of starting reagent was added to initiate the kinetic reaction. The change in absorption was monitored at 405 nm at 37 °C in an automated biochemistry analyser (Olympus AU600, Olympus Europe GmbH, Hamburg, Germany). The non-enzymatic hydrolysis of p-nitrophenyl acetate, based on the hydrolysis rate in the absence of serum, was subtracted from the total hydrolysis rate. Arylesterase activity was expressed as units per millilitre of serum, in which 1 U equals 1 µmol of phenyl acetate hydrolysed/min. The molar extinction coefficient used to calculate the rate of hydrolysis was 14,000 M⁻¹ cm⁻¹.

Statistical analysis

Associations between the clinical hepatometabolic phenotype and PON1 genetic variants (N = 790), epigenetic DNA methylation variation (N = 45), gene expression profile (N = 22) and enzymatic activity (N = 714) were examined in the HEPADIP cohort. Simultaneously, the occurrence of cis-meQTLs was assessed by looking whether the methylation levels of the PON1 promoter were influenced by one of the three examined PON1 polymorphisms. Pairwise comparison testing was performed by a linear regression analysis (continuous variable) or chi-squared test (categorical variable) in the different HEPADIP subsets (Additional file 1: Fig. S1). Both the significance level (p) and false discovery rate threshold (q, Benjamini–Hochberg) were set at 0.05. The number of tests for multiple testing correction was determined within each aim. Due to the limited availability of patient liver biopsy material of the different PON1 genotypes, genome-wide Illumina 450 K methylation array studies could not applied to verify further associations of PON1 SNPs with previously described trans-MeQTLs involved in metabolic health [27].

A targeted multi-omics approach was applied by designing (multinomial) logistic regression models. As the HEPADIP cohort is a highly detailed collection of patient samples with > 50 metabolic and hepatic parameters (including histology), data exploration via principal component analysis (PCA) was performed to identify and remove highly correlated variables (i.e. multicollinearity) from the statistical model. A multivariable regression model was used to study the combined impact of PON1 data parameters on the hepatometabolic phenotype. Confounding factors such as age, sex, medication and smoking/alcohol habits were also added in the model to verify whether PON1 variability independently influences the phenotype or not. PCA identified that all different drug treatment parameters considered in the HEPADIP study population (oral contraceptives, vitamins, hormones, diabetes medication, weight loss medication, blood pressure medication, lipid lowering medication) were highly interconnected, resulting in grouping of these different medication types into one combined single eigenvector (i.e. medical treatment variable.) All statistical analyses were carried out in R version 3.6.1.

All measured parameters (Sect. 5.1–5.6) were observed as explanatory and/or potential confounders for obesity and were as such included in statistical analyses. An overview of all tested correlations with their respective significance level (both significant and non-significant) can be found in Additional file 2: Table S6. Correlations that showed significance are described and discussed in detail throughout Sects. 2 and 3 of the main document.

Abbreviations

ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; apoA1: Apolipoprotein A1; AST: Aspartate aminotransferase; BMI: Body mass index; GGT: Gamma-glutamyltransferase; HEPADIP: Hepatic and adipose tissue functions and tissues in the metabolic syndrome; HDL: High-density-lipoproteins; LDL: Low-density-lipoproteins; meQTL: Methylation quantitative trait locus; M-values: Methylation values; NAFLD: Non-alcoholic fatty liver disease; NAS: NAFLD activity score; NASH: Non-alcoholic steatohepatitis; NASH-CRN: Non-alcoholic steatohepatitis clinical research network; PCA: Principal component analysis; PON1: Paraoxonase-1; SNP: Single nucleotide polymorphism; Sp1: Specific protein 1; SREBP-2: Sterol regulatory element-binding protein-2; TBBL: 5-Thiobutyl butyrolactone; TFBS: Transcription factor binding site; USS: Ultrasound steatosis score; WHR: Waist-to-hip ratio.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13148-021-01142-1.

Additional file 1. Supplementary tables and figures.

Additional file 2. Supplementary statistics table.

Acknowledgements

The authors gratefully acknowledge Bronwen Martin to proofread-edit the manuscript for language and style.

Authors’ information

The manuscript is a follow-up study on the paper by Declerck et al. [27].

Authors’ contributions

SD: experimental design; data acquisition, statistical analysis and interpretation; writing of original manuscript and editing. BC: statistical conceptualization and supervision of data analysis and interpretation; critical revision and final manuscript approval. AT: data acquisition; critical revision and final manuscript approval. BD: data acquisition; final manuscript approval. EVD: critical revision and final manuscript approval. AV: patient data acquisition and interpretation; critical revision and final manuscript approval. LVG: human sample collection; critical revision and final manuscript approval. KL: critical revision
and final manuscript approval. PL: supervision of data acquisition; critical revision and final manuscript approval. JJC: supervision of data acquisition; critical revision and final manuscript approval. SF: human sample collection; data interpretation; critical revision and final manuscript approval. WB: supervision of experimental design and data acquisition; data interpretation; critical revision and final manuscript approval. WVH: supervision experimental design and data acquisition; data interpretation; critical revision and final manuscript approval. All authors read and approved the final manuscript.

Funding
This study is part of the European Commission projects HEPADIP (Hepatic and adipose tissue and functions in the metabolic syndrome; Contract LSHM-CT-2005-018374) and RESOLVE (A systems biology approach to RESOLVE the molecular pathology of two hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol; contract FP7-205707) and was supported by Research grants of the University of Antwerp (GOA project: FFW180348/36652 & Methusalem-OEC Grant—"GENOMED"; FFW190208). BC has a postdoctoral fellow mandate from the Fund for Scientific Research (FWO) Flanders (12V5319N). EVD has a predoctoral fundamental research fellowship from the Fund for Scientific Research (FWO) Flanders (11E6921N). SF has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154N). All other contributing authors have nothing to disclose.

Availability of data and materials
Most data generated or analysed during this study are included in this published article and its Additional files. Additional datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
A written informed consent was obtained from each patient. The complete study protocol was performed according to the Declaration of Helsinki and approved by the Ethics Committee of the Antwerp University Hospital (EU consortium reference 6/25/125, Belgian registration number B30020071389). All authors had access to the study data and had reviewed and approved the final manuscript.

Consent for publication
Not applicable.

Competing interests
LVG is a member of District 57 Speakers Bureau and has a professional relationship with NovoNorisk and AstraZeneca.

Author details
1 Department of Medical Genetics, University of Antwerp, Prins Boudewijnaan 43, 2650 Edegem, Antwerp, Belgium. 2 Molecular Parasitology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium. 3 Adrem Data Lab, Department of Computer Science, University of Antwerp, Antwerp, Belgium. 4 Interdisciplinary Laboratory of Clinical Analysis INTER-LAB-UML, University of Murcia, Murcia, Spain. 5 Inserm, CHU Lille, Pasteur Institute of Lille, University of Lille, Lille, France. 6 Department of Endocrinology, Diabetology and Metabolic Disease, Antwerp University Hospital, Antwerp, Belgium. 7 Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium. 8 Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium. 9 Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Received: 2 February 2021 Accepted: 29 July 2021 Published online: 13 August 2021

References
1. Francque S. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In: Damme PV, Herck KV, Michielsen P, Francque S, Shouval D, editors. Chronic hepatitis and liver disease. Oxford textbook of public health. Oxford: O.U. Press; 2009. p. 1249–63.
2. Li L, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17(6):510–9.
3. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
4. Fabbri E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679–89.
5. Mantovani A, et al. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111:154170.
6. Fu Y, et al. Clinical features of COVID-19-infected patients with elevated liver biochemistries: a multicenter, retrospective study. Hepatology. 2020. https://doi.org/10.1002/hep.31446.
7. Van Gaal LF, Menten IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875–80.
8. Stunkard AJ, et al. An adoption study of human obesity. N Engl J Med. 1986;314(4):193–8.
9. Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA. 1986;256(1):51–4.
10. Sorensen TI. The genetics of obesity. Metabolism. 1995;44(9 Suppl 3):6–4.
11. Coady SA, et al. Genetic variability of adult body mass index: a longitudinal assessment in framingham families. Obes Res. 2002;10(7):675–81.
12. Locke AE, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206.
13. Shungin D, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015;518(7538):187–96.
14. Yenro L, et al. Meta-analysis of genome-wide association studies for height and body mass index in approximately 700000 individuals of European ancestry. Hum Mol Genet. 2018;27(20):3641–9.
15. Diels S, Vandenberghe W, Van Hul W. Insights into the multifactorial causation of obesity by integrated genetic and epigenetic analysis. Obes Rev. 2020;21(7):1–17.
16. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. Nutr Rev Gastroenterol Hepatol. 2020;71(1):40–52.
17. Bjorntson HT, Fallin MD, Feinberg AP. An integrated epigenetic and genetic approach to common human disease. Trends Genet. 2004;20(8):350–8.
18. Kappil M, Wright RO, Sanders AP. Developmental origins of common disease: epigenetic contributions to obesity. Annu Rev Genomics Hum Genet. 2016;17:177–92.
19. Voisin S, et al. Many obesity-associated SNPs strongly associate with DNA methylation changes at proximal promoters and enhancers. Genome Med. 2015;7:103.
20. Nuotio ML, et al. An epigenome-wide association study of metabolic syndrome and its components. Sci Rep. 2020;10(1):20567.
21. Gallou-Kabani C, Vige A, Junien C. Lifelong circadian and epigenetic drifts in metabolic syndrome. Epigenetics. 2007;2(3):137–46.
22. Berdasco M, Esteller M. Clinical epigenetics: seizing opportunities for translation. Nat Rev Genet. 2019;20(2):109–27.
23. Khorsonsksy O, Tawfik DS. Structure-reactivity studies of serum paraoxonase-1 (PON1) suggest that its native activity is lactonase. Biochemistry. 2005;44(16):6371–82.
24. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipo Peroxides in low-density lipoprotein. FEMS Lett. 1991;286(1–2):152–4.
25. Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12–21.
26. Rosenblat M, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281(11):7637–65.
27. Declerck K, et al. Interaction between prenatal pesticide exposure and a common polymorphism in the PON1 gene on DNA methylation in genes associated with cardio-metabolic disease risk-an exploratory study. Clin Epigenet. 2017;9:35.
28. Huen K, et al. Associations of PON1 and genetic ancestry with obesity in early childhood. PLoS ONE. 2013;8(5):e62565.
29. Desai S, et al. Paraoxonase 1 and oxidative stress in paediatric non-alcoholic steatohepatitis. Liver Int. 2014;34(1):110–7.
30. Huen K, et al. PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes. Environ Epigenet. 2015;1(1):dxv003.
31. Garcia-Heredia A, et al. Paraoxonase-1 deficiency is associated with severe liver steatosis in mice fed a high-fat high-cholesterol diet: a metabolicomic approach. J Proteome Res. 2013;12(4):1946–55.
32. Martinez-Salazar MF, et al. Relationship between the paraoxonase (PON1) L55M and Q192R polymorphisms and obesity in a Mexican population: a pilot study. Genes Nutr. 2011;6(4):361–8.
33. Barrett JC, et al. Haplovipe: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5.
34. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31.
35. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab. 2012;16(4):414–9.
36. Caballero F, et al. Enhanced free cholesterol, SREBP-2 and STAR expression in human NASH. J Hepatol. 2009;50(4):789–96.
37. Van Rooyen DM, et al. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011;141(4):1393–403.
38. Min HK, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012;15(5):665–74.
39. Musso G, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes. 2013;62(4):1109–20.
40. Briggs MR, et al. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science. 1986;234(4772):47–52.
41. Levey I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol. 2000;20(2):516–21.
42. Deakin S, et al. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position—107, implicating the Sp1 transcription factor. Biochem J. 2003;372(2):643–9.
43. Suehiro T, et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis. 2000;150(2):295–8.
44. Osaki F, et al. Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells. Atherosclerosis. 2004;176(2):279–87.
45. Holland N, Lizaraga D, Huen K. Recent progress in the genetics and epigenetics of paraoxonase: why it is relevant to children’s environmental health. Curr Opin Pediatr. 2015;27(2):240–7.
46. Blattler A, Fanhm PJ. Cross-talk between site-specific transcription factors and DNA methylation states. J Biol Chem. 2018;293(14):43287–94.
47. Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Acta. 2015;439:5–13.
48. Zheng RD, et al. Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2012;2012:2562147.
49. Gastaldelli A, Cusi K. From NAS to diabetes and from diabetes to NAFLD: mechanisms and treatment options. JHEP Rep. 2019;1(4):312–28.
50. Sorenson RC, et al. Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol. 1999;19(9):2214–25.
51. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015;439:5–13.
52. Bonder MJ, et al. Genetic and epigenetic regulation of gene expression in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10(10):1162–8.
53. Francque SM, et al. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2015;13(1):164–73.
54. Harel M, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11(5):412–9.
55. Shummoorgam N, Naidoo P, Chilton R. Paraoxonase (PON1): a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018;14:137–43.
56. Gaidukov I, et al. The 192/R polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolipase stimulation, and cholesterol efflux. J Lipid Res. 2006;47(11):2492–502.
57. Costa LG, et al. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005;69(4):541–50.
58. Francque SM, et al. Paraoxonase-1 deficiency is associated with severe liver steatosis independent of the metabolic syndrome. Exp Diabetes Res. 2012;2012:145754.
80. Skovierova H, et al. The molecular and cellular effect of homocysteine metabolism imbalance on human health. Int J Mol Sci. 2016;17(10):1733.
81. Draganov DI, et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46(6):1239–47.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.